We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+14.38%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$810M
AUM Growth
+$268M
Cap. Flow
+$286M
Cap. Flow %
35.27%
Top 10 Hldgs %
71.5%
Holding
51
New
7
Increased
2
Reduced
11
Closed
1

Top Buys

Rank Stock Value
1
LENZ
LENZ Therapeutics
LENZ
+$185M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$36.1M
3
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$28.7M
4
RXRX icon
Recursion Pharmaceuticals
RXRX
+$23M
5
JANX icon
Janux Therapeutics
JANX
+$13.5M

Top Sells

Rank Stock Value
1
CVAC
CureVac
CVAC
+$8.72M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$5.19M
3
TERN
Terns Pharmaceuticals
TERN
+$3.55M
4
VTGN icon
VistaGen Therapeutics
VTGN
+$2.71M
5
KRON
Kronos Bio
KRON
+$2.23M

Sector Composition

Rank Sector Weight
1 Healthcare 92.52%
2 Financials 1.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LENZ
1
LENZ Therapeutics
LENZ
$172M
$228M 28.19%
+1,061,660
New +$185M
NKTX icon
2
Nkarta
NKTX
$162M
$64.5M 7.96%
2,034,703
– –
KDNY
3
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$44.7M 5.52%
3,168,388
– –
NVAX icon
4
CALL
Novavax
NVAX
$1.23B
$42.2M 5.21%
198,600
– –
TIL icon
5
Instil Bio
TIL
$48.4M
$41.4M 5.12%
107,270
+29,569
+38% +$11M
FMTX
6
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$39M 4.81%
1,565,529
– –
CNTA
7
DELISTED
Centessa Pharmaceuticals
CNTA
$34.1M 4.22%
+1,537,533
New +$36.1M
STRO icon
8
Sutro Biopharma
STRO
$379M
$31.1M 3.85%
167,558
– –
RXRX icon
9
Recursion Pharmaceuticals
RXRX
$1.57B
$28.3M 3.49%
+775,583
New +$23M
RAIN
10
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$25.4M 3.14%
+1,637,308
New +$28.7M
JANX icon
11
Janux Therapeutics
JANX
$935M
$15.2M 1.87%
+607,949
New +$13.5M
SWTX
12
DELISTED
SpringWorks Therapeutics
SWTX
$14M 1.73%
169,852
– –
ACRS icon
13
Aclaris Therapeutics
ACRS
$730M
$13.9M 1.72%
794,171
-228,441
-22% -$5.19M
ISEE
14
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$13.4M 1.66%
2,125,371
-247,105
-10% -$1.59M
ICPT
15
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$12.8M 1.58%
640,688
– –
ELEV
16
DELISTED
Elevation Oncology
ELEV
$12.7M 1.56%
+932,239
New +$11.5M
ALLK
17
DELISTED
Allakos
ALLK
$12.5M 1.54%
146,259
– –
BOLT icon
18
Bolt Biotherapeutics
BOLT
$7.36M
$11.4M 1.41%
36,873
– –
SYRS
19
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$10.6M 1.31%
218,920
– –
VIRX
20
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$8.06M 1%
711,039
-120,586
-15% -$1.21M
VRNA
21
DELISTED
Verona Pharma
VRNA
$7.27M 0.9%
1,111,112
– –
DBTX
22
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$7.11M 0.88%
826,422
– –
ALLK
23
CALL
DELISTED
Allakos
ALLK
$7.09M 0.87%
83,000
– –
NVAX icon
24
Novavax
NVAX
$1.23B
$6.4M 0.79%
30,160
– –
SYRE icon
25
Spyre Therapeutics
SYRE
$8.87B
$6.15M 0.76%
35,349
– –
1
2 3

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
RIM
RW Investment Management Eagle, Idaho $1.03B AUM
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return

Samsara BioCapital's Q2 2021 Portfolio in Review

As of Q2 2021, Samsara BioCapital held 51 positions worth $810M, up 49% from $542M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Samsara BioCapital deployed $286M of net new capital in Q2 2021, opening 7 new positions and adding to 2 existing holdings. Its largest new stake was LENZ Therapeutics: 1,061,660 shares worth $228M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 90% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Aclaris Therapeutics, an estimated $5.19M trimmed.

  • Samsara BioCapital's largest Q2 2021 buy was LENZ Therapeutics: 1,061,660 shares worth $228M.
  • Samsara BioCapital added most to Instil Bio in Q2 2021, an estimated $11M increase.
  • Samsara BioCapital's biggest Q2 2021 reduction was Aclaris Therapeutics, cutting an estimated $5.19M.
  • Samsara BioCapital fully exited CureVac in Q2 2021, selling an estimated $8.72M.
  • Samsara BioCapital's ten largest holdings make up 72% of its $810M portfolio in Q2 2021.
  • Samsara BioCapital opened 7 new positions and closed 1 in Q2 2021.
  • Samsara BioCapital's portfolio value rose 49% quarter-over-quarter to $810M.

Based on Samsara BioCapital's 13F filing for Q2 2021, filed 17 Aug 2021.